Innate Pharma Announces Its Participation in Upcoming Investor Conferences
Innate Pharma (Nasdaq: IPHA) has announced its upcoming participation in several major healthcare investor conferences. The company's executive team will attend five prestigious events between November and December 2024, including the Stifel Healthcare Conference and Jefferies London Healthcare Conference in mid-November, followed by the Wolfe Healthcare Conference in New York. In early December, the team will participate in the 7th Annual Evercore ISI HealthCONx Conference and Citi's Global Healthcare Conference, both taking place in Miami.
Innate Pharma (Nasdaq: IPHA) ha annunciato la sua prossima partecipazione a diverse importanti conferenze per investitori nel settore sanitario. Il team esecutivo dell'azienda parteciperà a cinque prestigiosi eventi tra novembre e dicembre 2024, inclusi il Stifel Healthcare Conference e il Jefferies London Healthcare Conference a metà novembre, seguiti dal Wolfe Healthcare Conference a New York. All'inizio di dicembre, il team prenderà parte al 7th Annual Evercore ISI HealthCONx Conference e al Citi's Global Healthcare Conference, entrambi si svolgeranno a Miami.
Innate Pharma (Nasdaq: IPHA) ha anunciado su próxima participación en varias importantes conferencias de inversores en el sector de la salud. El equipo ejecutivo de la empresa asistirá a cinco eventos prestigiosos entre noviembre y diciembre de 2024, incluidos la Stifel Healthcare Conference y la Jefferies London Healthcare Conference a mediados de noviembre, seguidas de la Wolfe Healthcare Conference en Nueva York. A principios de diciembre, el equipo participará en la 7th Annual Evercore ISI HealthCONx Conference y la Citi's Global Healthcare Conference, ambas que se llevarán a cabo en Miami.
Innate Pharma (Nasdaq: IPHA)는 여러 주요 헬스케어 투자자 회의에 참가할 예정이라고 발표했습니다. 회사의 경영진 팀은 2024년 11월과 12월 사이에 Stifel Healthcare Conference와 Jefferies London Healthcare Conference를 포함하여 다섯 개의 유명 이벤트에 참석할 예정입니다. 중순에 뉴욕에서 열리는 Wolfe Healthcare Conference가 이어집니다. 12월 초에는 마이애미에서 열리는 7th Annual Evercore ISI HealthCONx Conference와 Citi's Global Healthcare Conference에 참가할 것입니다.
Innate Pharma (Nasdaq: IPHA) a annoncé sa prochaine participation à plusieurs grandes conférences d'investisseurs dans le secteur de la santé. L'équipe de direction de l'entreprise assistera à cinq événements prestigieux entre novembre et décembre 2024, y compris la Stifel Healthcare Conference et la Jefferies London Healthcare Conference à la mi-novembre, suivies de la Wolfe Healthcare Conference à New York. Début décembre, l'équipe participera à la 7th Annual Evercore ISI HealthCONx Conference et à la Citi's Global Healthcare Conference, toutes deux se déroulant à Miami.
Innate Pharma (Nasdaq: IPHA) hat seine bevorstehenden Teilnahmen an mehreren wichtigen Investorenkonferenzen im Gesundheitssektor bekannt gegeben. Das Führungsteam des Unternehmens wird zwischen November und Dezember 2024 an fünf prestigeträchtigen Veranstaltungen teilnehmen, darunter die Stifel Healthcare Conference und die Jefferies London Healthcare Conference Mitte November, gefolgt von der Wolfe Healthcare Conference in New York. Anfang Dezember wird das Team an der 7th Annual Evercore ISI HealthCONx Conference und der Citi's Global Healthcare Conference teilnehmen, die beide in Miami stattfinden.
- None.
- None.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team are scheduled to participate in the upcoming investor conferences, detailed below.
-
Stifel Healthcare Conference
Event dates: November 18 – 19, 2024 |New York ,United States
-
Jefferies London Healthcare Conference
Event dates: November 19 – 21, 2024 |London ,Europe
-
Wolfe Healthcare Conference
Event dates: November 19 – 20, 2024 |New York ,United States
-
7th Annual Evercore ISI HealthCONx Conference
Event dates: December 3 – 5, 2024 |Miami ,United States
-
Citi’s Global Healthcare Conference
Event dates: December 3 – 5, 2024 |Miami ,United States
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: monoclonal antibodies, multi-specific NK Cell Engagers via its ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC).
Innate’s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, several ANKET® drug candidates to address multiple tumor types as well as IPH4502 a differentiated ADC in development in solid tumors.
Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.
Headquartered in
Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.
Information about Innate Pharma shares
ISIN code
|
FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 |
Disclaimer on forward-looking information and risk factors
This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “may,” “might,” “potential,” “expect” “should,” “will,” or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s reliance on third parties to manufacture its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website (www.innate-pharma.com), and public filings and reports filed with the
In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241028133823/en/
For additional information, please contact:
Investors
Innate Pharma
Henry Wheeler
Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
Media Relations
NewCap
Arthur Rouillé
Tel.: +33 (0)1 44 71 00 15
innate@newcap.eu
Source: Innate Pharma SA
FAQ
Which investor conferences will Innate Pharma (IPHA) attend in November 2024?
What conferences is Innate Pharma (IPHA) scheduled to attend in Miami during December 2024?